

APPENDIX A

IN THE SPECIFICATION

In the paragraph on page 1, lines 3-6:

This application [claims priority] is a continuation of PCT International application number PCT/US02/01797, filed January 22, 2002, which claims benefit of [to] United States Provisional Application Number 60/263,416, filed January 22, 2001[, the disclosure which is]. The disclosures of International application PCT/US02/01797 and United States provisional application 60/263,416 are incorporated by reference herein.

APPENDIX B

IN THE CLAIMS

1. (Amended) A method for increasing the level of a therapeutic gene product in a subject, the method comprising administering to said subject a first viral vector [comprising] which comprises a therapeutic nucleic acid encoding said therapeutic gene product and an agent that modulates Kupffer cell function in said subject, wherein said agent is a second viral vector that does not comprise said therapeutic nucleic acid.